Work for Satsuma Pharmaceuticals, Inc.?

Claim Your Profile

Satsuma Pharmaceuticals, Inc. Logo Image

Satsuma Pharmaceuticals, Inc.

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. has reached its limit for free report views.

About Satsuma Pharmaceuticals, Inc.

11-50 Employees
Based in South San Francisco, California

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.

Ticker:
STSA
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol